Horizon scanning: Phase 2 trial investigates two dosing regimens of tosedostat in elderly patients with relapsed or refractory AML

Source: Lancet Oncology Area: News The results of this small randomised phase 2 open label study, investigating two doses of tosedostat, suggest that the drug has activity in older patients with relapsed or refractory acute myeloid leukaemia (AML) at either dose schedule. Tosedostat is being developed as an oral agent which inhibits aminopeptidases - thought to have a key role in the protein cell cycle. The study randomised (1:1 ratio) patients aged over 60 years with AML that had relapsed after a first complete remission lasting less than 12 months, or had achieved no previous complete remission to either first salvage tosedostat 120 mg once daily for 6 months (n=38) or 240 mg once daily for 2 months followed by 120 mg (n=38) for 4 months. The primary endpoint measure considered in the study was the proportion of patients who obtained a complete remission or complete remission with incomplete platelet recovery. Analyses of the results included all patients randomised to treatment who received at least one oral dose ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news